Orelabrutinib is under investigation in clinical trial NCT04305197 (A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)).
⑴既往至少接受过一种治疗的成人套细胞淋巴瘤(MCL)患者。
⑵既往至少接受过一种治疗的成人慢性淋巴细胞白血病(CLL)/小淋巴细胞淋巴瘤(SLL)患者。
Department of Hematology, Huashan Hospital, Fudan University, Shanghai, China
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Auhui, China
Beijing Tongren Hospital, Capital Medical University, Beijing, Beijing, China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Hematological Department, People's Hospital of Jiangsu Province, Nanjing, Jiangsu, China
The first affiliated hospital of bengbu medical college, Bengbu, Anhui, China
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
Beijing CHAO-YANG Hospital Capital Medcal University, Beijing, Beijing, China
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Beijing GoBroad Boren Hospital, Beijing, China
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hanzhou, Zhejiang, China
the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.